Newton, Massachusetts – April 2015. 

NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds announces that Neal M. Farber, Ph.D., Chief Executive Officer, will present an overview of NH001 at the World Orphan Drug Congress USA taking place at the Washington Hilton, Washington D.C., April 23-24 2015.  NH001 is the Company’s investigational candidate to enable patients to emerge from a coma, vegetative and minimally conscience state.

This 5th annual World Orphan Drug Congress 2015 brings together orphan drug stakeholders and global leaders in the rare disease industry to address the latest strategies for product development, commercialization, reimbursement, sustainability, and global market access.  More than 800 attendees from 40 countries are expected to attend.

About the author